-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yimaitong compiles and organizes, please do not reprint without authorization
.
Recently, a retrospective cohort study from Taiwan of China evaluated whether metformin monotherapy or combination therapy can help reduce the risk of anemia in patients with type 2 diabetes and advanced chronic kidney disease (CKD)
.
Research description The research data set comes from the Taiwan Health Insurance Research Database
.
After 1:1 matching, 9303 pairs of metformin and non-metformin users were obtained
.
Between 1997 and 2012, each patient was recorded separately to determine the incidence of anemia (hemoglobin less than 9gm/dL)
.
The Cox regression model was used to calculate the hazard ratio and 95% confidence interval
.
Metformin combined with DPP-4i can help reduce the occurrence of anemia.
During the average follow-up period of 6.
8 years and 5.
6 years, there were 305 (0.
7%) and 76 (0.
8%) erythropoietin stimulators (ESA) in the metformin and non-metformin cohorts, respectively Use cases
.
After matching analysis, the use of metformin reduced the risk of ESA use by 24% to 70%.
The adjusted hazard ratio (HR): 0.
76 (95% CI 0.
45-1.
29) for the dose<357g group; 0.
30 for the dose>1368g group ( 95%CI 0.
17-0.
56)
.
In addition, the combination of metformin and DPP-4i reduced the risk by 58% compared with metformin alone (HR 0.
42, 95% CI 0.
18-0.
99)
.
Research conclusions Metformin combined with DPP-4i is superior to metformin monotherapy or non-metformin antidiabetic therapy in reducing the risk of anemia in the progression of advanced chronic kidney disease in type 2 diabetic patients
.
Yimaitong compiled and compiled from: Hussein M, Fathy W, Hassan A, et al.
Zinc deficiency correlates with severity of diabetic polyneuropathy[J].
Brain Behav, 2021:e32349.
.
Recently, a retrospective cohort study from Taiwan of China evaluated whether metformin monotherapy or combination therapy can help reduce the risk of anemia in patients with type 2 diabetes and advanced chronic kidney disease (CKD)
.
Research description The research data set comes from the Taiwan Health Insurance Research Database
.
After 1:1 matching, 9303 pairs of metformin and non-metformin users were obtained
.
Between 1997 and 2012, each patient was recorded separately to determine the incidence of anemia (hemoglobin less than 9gm/dL)
.
The Cox regression model was used to calculate the hazard ratio and 95% confidence interval
.
Metformin combined with DPP-4i can help reduce the occurrence of anemia.
During the average follow-up period of 6.
8 years and 5.
6 years, there were 305 (0.
7%) and 76 (0.
8%) erythropoietin stimulators (ESA) in the metformin and non-metformin cohorts, respectively Use cases
.
After matching analysis, the use of metformin reduced the risk of ESA use by 24% to 70%.
The adjusted hazard ratio (HR): 0.
76 (95% CI 0.
45-1.
29) for the dose<357g group; 0.
30 for the dose>1368g group ( 95%CI 0.
17-0.
56)
.
In addition, the combination of metformin and DPP-4i reduced the risk by 58% compared with metformin alone (HR 0.
42, 95% CI 0.
18-0.
99)
.
Research conclusions Metformin combined with DPP-4i is superior to metformin monotherapy or non-metformin antidiabetic therapy in reducing the risk of anemia in the progression of advanced chronic kidney disease in type 2 diabetic patients
.
Yimaitong compiled and compiled from: Hussein M, Fathy W, Hassan A, et al.
Zinc deficiency correlates with severity of diabetic polyneuropathy[J].
Brain Behav, 2021:e32349.
